Purpose

This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.

Conditions

Eligibility

Eligible Ages
All ages
Eligible Sex
All
Accepts Healthy Volunteers
No

Criteria

Inclusion Criteria:

- Participants must have been assigned to S1900K by the Southwest Oncology Group
(SWOG) Statistics and Data Management Center (SDMC). Assignment to S1900K is
determined by the LUNGMAP protocol

- Participants must have documentation of NSCLC with a MET exon 14 skipping mutation
determined by tissue-based or blood-based (circulating tumor DNA [ctDNA]) next
generation sequencing (NGS) assay done within a laboratory with Clinical Laboratory
Improvement Act (CLIA), International Organization for Standardization (ISO)/
International Electrotechnical Commission (IEC), College of American Pathologists
(CAP), or similar certification. Documentation must either be:

- NGS test results from tissue submitted for LUNGMAP screening, or

- Submitted documentation in the LUNGMAP Rave Electronic Data Capture System of a
MET exon 14 skipping mutation from a previously completed tissue or blood-based
NGS test NOTE: Participants previously tested for and determined to have a MET
exon 14 skipping mutation, outside of LUNGMAP, must also submit tissue for
central Foundation Medicine (FMI) testing on the LUNGMAP screening protocol, if
available

- Participants must have measurable disease documented by CT or MRI. The CT from a
combined positron emission tomography (PET)/CT may be used to document measurable
disease ONLY if it is of diagnostic quality, otherwise, it may be used to document
non-measurable disease only. Measurable disease must be assessed within 28 days
prior to sub-study randomization. Pleural effusions, ascites and laboratory
parameters are not acceptable as the only evidence of disease. Non-measurable
disease must be assessed within 42 days prior to sub-study randomization. All known
sites of disease must be assessed and documented on the Baseline Tumor Assessment
Form. Participants whose only measurable disease is within a previous radiation
therapy port must demonstrate clearly progressive disease (in the opinion of the
treating investigator) prior to sub-study randomization to be considered measurable

- Participants must have a CT or MRI scan of the brain to evaluate for central nervous
system (CNS) disease within 42 days prior to sub-study randomization

- Participants must not have leptomeningeal disease, spinal cord compression or brain
metastases unless:

- Metastases have been locally treated and have remained clinically controlled
and asymptomatic for at least 3 days following the stereotactic radiation
and/or 14 days following whole brain radiation, and prior to sub-study
randomization, AND

- Participant has no residual neurological dysfunction and has been off
corticosteroids for at least 24 hours prior to sub-study randomization

- Participants must not have other known actionable oncogenic alterations, such as
(but not limited to) EGFR sensitizing mutations, EGFR T790M mutation, ALK gene
fusion, ROS1 gene rearrangement, RET gene rearrangement, NTRK rearrangement, HER2
mutation, KRAS activating mutations, and BRAF V600E mutation

- Participants must have progressed (in the opinion of the treating physician)
following the most recent line of therapy

- Participants must have received at least one line of systemic treatment for Stage IV
or recurrent NSCLC

- Participants must have recovered (=< grade 1) from any side effects of prior therapy
except alopecia and vitiligo

- Participants must not have received any prior systemic therapy (systemic
chemotherapy, immunotherapy or investigational drug) within 21 days prior to
sub-study randomization

- Participants must not have received treatment with prior MET inhibitor therapies
(e.g., crizotinib, tivantinib, savolitinib, tepotinib, cabozantinib, and foretinib).

- Participants must not have received treatment with prior angiogenesis inhibitor
therapies (including but not limited to bevacizumab and ramucirumab)

- Participants must not have a history of interstitial lung disease that required
steroid treatment

- Participants must not have received any radiation therapy within 7 days prior to
sub-study randomization with the exceptions of

- Stereotactic radiation to CNS metastases which must have been completed at
least 3 days prior to sub-study randomization and

- Palliative radiotherapy to bone metastases which must have been completed at
least 1 day prior to sub-study randomization

- Participants must not be planning to receive any concurrent chemotherapy,
immunotherapy, biologic or hormonal therapy for cancer treatment while receiving
treatment on this study

- Participants must not have had a major surgery within 14 days prior to sub-study
randomization. Participants must have fully recovered from the effects of prior
surgery in the opinion of the treating investigator

- Participants must not have a prior or concurrent malignancy whose natural history or
treatment (in the opinion of the treating physician) has the potential to interfere
with the safety or efficacy assessment of the investigational regimen

- Participants must be able to swallow tablets whole

- Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to sub-study
randomization)

- Hemoglobin >= 9.0 g/dL (within 28 days prior to sub-study randomization)

- Platelets >= 100 x 10^3/uL (within 28 days prior to sub-study randomization)

- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) unless history of
Gilbert's disease. Participants with history of Gilbert's disease must have total
bilirubin =< 5 x institutional ULN (within 28 days prior to sub-study randomization)

- Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) =< 2.5 ×
institutional ULN. Participants with history of liver metastasis must have AST =< 5
x ULN (within 28 days prior to sub-study randomization)

- Participants must have a serum creatinine =< the institutional upper limit of normal
(IULN) or calculated creatinine clearance >= 30 mL/min using the following
Cockcroft-Gault Formula. This specimen must have been drawn and processed within 28
days prior to sub-study randomization

- Participants must have a cystatin C test performed to obtain baseline value within
28 days prior to sub-study randomization

- Participants' most recent Zubrod performance status must be 0-1 and be documented
within 28 days prior to sub-study randomization

- Participants must have a completed medical history and physical exam within 28 days
prior to sub-study randomization

- Participants must have adequate cardiac function. Participants with known history or
current symptoms of cardiac disease, or history of treatment with cardiotoxic
agents, must have a clinical risk assessment of cardiac function using the New York
Heart Association Functional Classification. To be eligible for this trial,
participants must be class 2B or better

- Participants with known human immunodeficiency virus (HIV)-infection must be on
effective anti-retroviral therapy and have undetectable viral load test on the most
recent test results obtained within 6 months prior to sub-study randomization

- Participants with evidence of chronic hepatitis B virus (HBV) infection must have
undetectable HBV viral load while on suppressive therapy on the most recent test
results obtained within 6 months prior to sub-study randomization, if indicated

- Participants with a history of hepatitis C virus (HCV) infection must have been
treated and cured. Participants currently being treated for HCV infection must have
undetectable HCV viral load test on the most recent test results obtained within 6
months prior to sub-study randomization, if indicated by the treating investigator

- Participants must not have cirrhosis at a level of Child-Pugh B (or worse) OR any
degree of cirrhosis AND a history of hepatic encephalopathy or clinically meaningful
ascites resulting from cirrhosis

- Participants must not have grade < 0 of peripheral edema within 28 days prior to
sub-study randomization

- Participants must not have experienced any arterial thromboembolic events, including
but not limited to transient ischemic attack or cerebrovascular accident within 6
months prior to sub-study randomization

- Participants must not have uncontrolled blood pressure and hypertension within 28
days prior to sub-study randomization

- Participants must not be pregnant or breastfeeding (nursing includes breast milk fed
to an infant by any means, including from the breast, milk expressed by hand, or
pumped). Individuals who are of reproductive potential must have agreed to use an
effective contraceptive method with details provided as a part of the consent
process. A person who has had menses at any time in the preceding 12 consecutive
months or who has semen likely to contain sperm is considered to be of "reproductive
potential." In addition to routine contraceptive methods, "effective contraception"
also includes refraining from sexual activity that might result in pregnancy and
surgery intended to prevent pregnancy (or with a side-effect of pregnancy
prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal
ligation/occlusion, and vasectomy with testing showing no sperm in the semen

- Participants must have a Lymphoscintigraphy scan performed within 28 days prior to
sub-study randomization

- Participants must also be offered participation in specimen banking. With
participant consent, specimens must be collected and submitted via the SWOG Specimen
Tracking System

- Participants must be informed of the investigational nature of this study and must
sign and give informed consent in accordance with institutional and federal
guidelines

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A: (Ramucirumab and tepotinib)
Patients receive ramucirumab IV over 30-60 minutes on day 1 of each cycle and tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan and CT scan and/or MRI throughout the trial. Patients also undergo blood sample collection while on study.
  • Procedure: Biospecimen Collection
    Undergo blood sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Procedure: Computed Tomography
    Undergo CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Procedure: Lymphoscintigraphy
    Undergo lymphoscintigraphy scan
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Biological: Ramucirumab
    Given IV
    Other names:
    • Anti-VEGFR-2 Fully Human Monoclonal Antibody IMC-1121B
    • Cyramza
    • IMC-1121B
    • LY3009806
    • Monoclonal Antibody HGS-ETR2
  • Drug: Tepotinib
    Given PO
    Other names:
    • c-Met Inhibitor MSC2156119J
    • EMD 1214063
    • EMD-1214063
    • EMD1214063
    • MSC2156119J
Active Comparator
Arm B: (Tepotinib)
Patients receive tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan and CT scan and/or MRI throughout the trial. Patients also undergo blood sample collection while on study.
  • Procedure: Biospecimen Collection
    Undergo blood sample collection
    Other names:
    • Biological Sample Collection
    • Biospecimen Collected
    • Specimen Collection
  • Procedure: Computed Tomography
    Undergo CT scan
    Other names:
    • CAT
    • CAT Scan
    • Computed Axial Tomography
    • Computerized Axial Tomography
    • Computerized axial tomography (procedure)
    • Computerized Tomography
    • CT
    • CT Scan
    • tomography
  • Procedure: Lymphoscintigraphy
    Undergo lymphoscintigraphy scan
  • Procedure: Magnetic Resonance Imaging
    Undergo MRI
    Other names:
    • Magnetic Resonance
    • Magnetic resonance imaging (procedure)
    • Magnetic Resonance Imaging Scan
    • Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    • MR
    • MR Imaging
    • MRI
    • MRI Scan
    • NMR Imaging
    • NMRI
    • Nuclear Magnetic Resonance Imaging
  • Drug: Tepotinib
    Given PO
    Other names:
    • c-Met Inhibitor MSC2156119J
    • EMD 1214063
    • EMD-1214063
    • EMD1214063
    • MSC2156119J

Recruiting Locations

NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
Jonesboro 4116834, Arkansas 4099753 72401
Contact:
Site Public Contact
870-936-7066
Emily.Carvell@bmhcc.org

University of Arkansas for Medical Sciences
Little Rock 4119403, Arkansas 4099753 72205
Contact:
Site Public Contact
501-686-8274

Kaiser Permanente-Anaheim
Anaheim 5323810, California 5332921 92806
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Sutter Auburn Faith Hospital
Auburn 5325223, California 5332921 95602
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-Baldwin Park
Baldwin Park 5325866, California 5332921 91706
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-Bellflower
Bellflower 5327422, California 5332921 90706
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Alta Bates Summit Medical Center-Herrick Campus
Berkeley 5327684, California 5332921 94704
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Tower Cancer Research Foundation
Beverly Hills 5328041, California 5332921 90211
Contact:
Site Public Contact
towercancerresearch@toweroncology.com

Kaiser Permanente-Fontana
Fontana 5349755, California 5332921 92335
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Palo Alto Medical Foundation-Fremont
Fremont 5350734, California 5332921 94538
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente South Bay
Harbor City 5355325, California 5332921 90710
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-Irvine
Irvine 5359777, California 5332921 92618
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente Los Angeles Medical Center
Los Angeles 5368361, California 5332921 90027
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente West Los Angeles
Los Angeles 5368361, California 5332921 90034
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Cedars Sinai Medical Center
Los Angeles 5368361, California 5332921 90048
Contact:
Site Public Contact
310-423-8965

Memorial Medical Center
Modesto 5373900, California 5332921 95355
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-Ontario
Ontario 5379439, California 5332921 91761
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Palo Alto Medical Foundation Health Care
Palo Alto 5380748, California 5332921 94301
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente - Panorama City
Panorama City 5380932, California 5332921 91402
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Kaiser Permanente-Riverside
Riverside 5387877, California 5332921 92505
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Sutter Roseville Medical Center
Roseville 5388881, California 5332921 95661
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Sutter Medical Center Sacramento
Sacramento 5389489, California 5332921 95816
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

University of California Davis Comprehensive Cancer Center
Sacramento 5389489, California 5332921 95817
Contact:
Site Public Contact
916-734-3089

Kaiser Permanente-San Diego Zion
San Diego 5391811, California 5332921 92120
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

California Pacific Medical Center-Pacific Campus
San Francisco 5391959, California 5332921 94115
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-San Marcos
San Marcos 5392368, California 5332921 92078
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

Palo Alto Medical Foundation-Santa Cruz
Santa Cruz 5393052, California 5332921 95065
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Sutter Pacific Medical Foundation
Santa Rosa 5393287, California 5332921 95403
Contact:
Site Public Contact
415-209-2683
clinicalresearch@sutterhealth.org

Palo Alto Medical Foundation-Sunnyvale
Sunnyvale 5400075, California 5332921 94086
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Cedars-Sinai Cancer - Tarzana
Tarzana 5401143, California 5332921 91356
Contact:
Site Public Contact
818-981-3818

Torrance Memorial Physician Network - Cancer Care
Torrance 5403022, California 5332921 90505
Contact:
Site Public Contact
310-750-3300
courtney.steeneken@tmphysicians.com

Sutter Solano Medical Center/Cancer Center
Vallejo 5405380, California 5332921 94589
Contact:
Site Public Contact
clinicalresearch@sutterhealth.org

Kaiser Permanente-Woodland Hills
Woodland Hills 5410438, California 5332921 91367
Contact:
Site Public Contact
800-398-3996
clinical.trials@kp.org

UCHealth University of Colorado Hospital
Aurora 5412347, Colorado 5417618 80045
Contact:
Site Public Contact
720-848-0650

UCHealth Memorial Hospital Central
Colorado Springs 5417598, Colorado 5417618 80909
Contact:
Site Public Contact
719-365-2406

Memorial Hospital North
Colorado Springs 5417598, Colorado 5417618 80920
Contact:
Site Public Contact
719-364-6700

Poudre Valley Hospital
Fort Collins 5577147, Colorado 5417618 80524
Contact:
Site Public Contact
970-297-6150

Cancer Care and Hematology-Fort Collins
Fort Collins 5577147, Colorado 5417618 80528
Contact:
Site Public Contact
protocols@swog.org

UCHealth Greeley Hospital
Greeley 5577592, Colorado 5417618 80631
Contact:
Site Public Contact
protocols@swog.org

Medical Center of the Rockies
Loveland 5579368, Colorado 5417618 80538
Contact:
Site Public Contact
970-203-7083

Smilow Cancer Hospital-Derby Care Center
Derby 4832745, Connecticut 4831725 06418
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center-Fairfield
Fairfield 4834157, Connecticut 4831725 06824
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Glastonbury
Glastonbury 4835003, Connecticut 4831725 06033
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Greenwich
Greenwich 4835395, Connecticut 4831725 06830
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center - Guilford
Guilford 4835512, Connecticut 4831725 06437
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Saint Francis
Hartford 4835797, Connecticut 4831725 06105
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Yale University
New Haven 4839366, Connecticut 4831725 06520
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Yale-New Haven Hospital North Haven Medical Center
North Haven 4839704, Connecticut 4831725 06473
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center at Long Ridge
Stamford 4843564, Connecticut 4831725 06902
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital-Torrington Care Center
Torrington 4844309, Connecticut 4831725 06790
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center-Trumbull
Trumbull 4844459, Connecticut 4831725 06611
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital-Waterbury Care Center
Waterbury 4845193, Connecticut 4831725 06708
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Smilow Cancer Hospital Care Center - Waterford
Waterford 8480031, Connecticut 4831725 06385
Contact:
Site Public Contact
203-785-5702
canceranswers@yale.edu

Bayhealth Hospital Kent Campus
Dover 4142290, Delaware 4142224 19901
Contact:
Site Public Contact
302-674-4401
clinical_trials@bayhealth.org

Bayhealth Hospital Sussex Campus
Milford 4143658, Delaware 4142224 19963
Contact:
Site Public Contact
302-674-4401
clinical_trials@bayhealth.org

Kaiser Permanente-Capitol Hill Medical Center
Washington D.C. 4140963, District of Columbia 4138106 20002
Contact:
Site Public Contact
301-548-5743

Northeast Georgia Medical Center-Gainesville
Gainesville 4196586, Georgia 4197000 30501
Contact:
Site Public Contact
770-219-8800
cancerpatient.navigator@nghs.com

Saint Alphonsus Cancer Care Center-Boise
Boise 5586437, Idaho 5596512 83706
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Saint Alphonsus Cancer Care Center-Caldwell
Caldwell 5587698, Idaho 5596512 83605
Contact:
Site Public Contact
734-712-3671
stephanie.couch@stjoeshealth.org

Kootenai Health - Coeur d'Alene
Coeur d'Alene 5589173, Idaho 5596512 83814
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Saint Alphonsus Cancer Care Center-Nampa
Nampa 5601933, Idaho 5596512 83687
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Kootenai Clinic Cancer Services - Post Falls
Post Falls 5604353, Idaho 5596512 83854
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Kootenai Clinic Cancer Services - Sandpoint
Sandpoint 5606401, Idaho 5596512 83864
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Illinois CancerCare-Bloomington
Bloomington 4885164, Illinois 4896861 61704
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Canton
Canton 4831990, Illinois 4896861 61520
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Carthage
Carthage 4886716, Illinois 4896861 62321
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern University
Chicago 4887398, Illinois 4896861 60611
Contact:
Site Public Contact
312-695-1301
cancer@northwestern.edu

John H Stroger Jr Hospital of Cook County
Chicago 4887398, Illinois 4896861 60612
Contact:
Site Public Contact
312-864-5204

Carle at The Riverfront
Danville 4889426, Illinois 4896861 61832
Contact:
Site Public Contact
800-446-5532
Research@Carle.com

Cancer Care Specialists of Illinois - Decatur
Decatur 4236895, Illinois 4896861 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Decatur Memorial Hospital
Decatur 4236895, Illinois 4896861 62526
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Cancer Center Kishwaukee
DeKalb 4889553, Illinois 4896861 60115
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Illinois CancerCare-Dixon
Dixon 4889959, Illinois 4896861 61021
Contact:
Site Public Contact
815-285-7800

Carle Physician Group-Effingham
Effingham 4237727, Illinois 4896861 62401
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Crossroads Cancer Center
Effingham 4237727, Illinois 4896861 62401
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Illinois CancerCare-Eureka
Eureka 4891310, Illinois 4896861 61530
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Galesburg
Galesburg 4893392, Illinois 4896861 61401
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Cancer Center Delnor
Geneva 4893591, Illinois 4896861 60134
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Northwestern Medicine Glenview Outpatient Center
Glenview 4893886, Illinois 4896861 60026
Contact:
Site Public Contact
312-695-1102

Northwestern Medicine Grayslake Outpatient Center
Grayslake 4894465, Illinois 4896861 60030
Contact:
Site Public Contact
312-695-1102

Edward Hines Jr VA Hospital
Hines 4896005, Illinois 4896861 60141
Contact:
Site Public Contact
708-202-8387

Illinois CancerCare-Kewanee Clinic
Kewanee 4898433, Illinois 4896861 61443
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Northwestern Medicine Lake Forest Hospital
Lake Forest 4899012, Illinois 4896861 60045
Contact:
Site Public Contact
cancertrials@northwestern.edu

Illinois CancerCare-Macomb
Macomb 4900817, Illinois 4896861 61455
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Carle Physician Group-Mattoon/Charleston
Mattoon 4244099, Illinois 4896861 61938
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Cancer Care Center of O'Fallon
O'Fallon 4245926, Illinois 4896861 62269
Contact:
Site Public Contact
217-876-4762
morganthaler.jodi@mhsil.com

Northwestern Medicine Orland Park
Orland Park 4904937, Illinois 4896861 60462
Contact:
Site Public Contact
nctnprogram_rhlccc@northwestern.edu

Illinois CancerCare-Ottawa Clinic
Ottawa 4905006, Illinois 4896861 61350
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Pekin
Pekin 4905599, Illinois 4896861 61554
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peoria
Peoria 4905687, Illinois 4896861 61615
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Peru
Peru 4905770, Illinois 4896861 61354
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Illinois CancerCare-Princeton
Princeton 4906818, Illinois 4896861 61356
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Memorial Hospital East
Shiloh 4249910, Illinois 4896861 62269
Contact:
Site Public Contact
314-747-9912
dschwab@wustl.edu

Southern Illinois University School of Medicine
Springfield 4250542, Illinois 4896861 62702
Contact:
Site Public Contact
217-545-7929

Springfield Clinic
Springfield 4250542, Illinois 4896861 62702
Contact:
Site Public Contact
800-444-7541

Springfield Memorial Hospital
Springfield 4250542, Illinois 4896861 62781
Contact:
Site Public Contact
217-528-7541
pallante.beth@mhsil.com

Carle Cancer Center
Urbana 4914570, Illinois 4896861 61801
Contact:
Site Public Contact
800-446-5532
Research@carle.com

Northwestern Medicine Cancer Center Warrenville
Warrenville 4915525, Illinois 4896861 60555
Contact:
Site Public Contact
630-352-5360
Donald.Smith3@nm.org

Illinois CancerCare - Washington
Washington 4915545, Illinois 4896861 61571
Contact:
Site Public Contact
309-243-3605
andersonj@illinoiscancercare.com

Indiana University/Melvin and Bren Simon Cancer Center
Indianapolis 4259418, Indiana 4921868 46202
Contact:
Site Public Contact
317-278-5632
iutrials@iu.edu

Mary Greeley Medical Center
Ames 4846834, Iowa 4862182 50010
Contact:
Site Public Contact
515-956-4132

McFarland Clinic - Ames
Ames 4846834, Iowa 4862182 50010
Contact:
Site Public Contact
515-239-4734
ksoder@mcfarlandclinic.com

Mission Cancer and Blood - Ankeny
Ankeny 4846960, Iowa 4862182 50023
Contact:
Site Public Contact
515-241-3305

McFarland Clinic - Boone
Boone 4849051, Iowa 4862182 50036
Contact:
Site Public Contact
515-956-4132

Iowa Methodist Medical Center
Des Moines 4853828, Iowa 4862182 50309
Contact:
Site Public Contact
515-241-6727

Mission Cancer and Blood - Des Moines
Des Moines 4853828, Iowa 4862182 50309
Contact:
Site Public Contact
515-241-3305

McFarland Clinic - Trinity Cancer Center
Fort Dodge 4857486, Iowa 4862182 50501
Contact:
Site Public Contact
515-956-4132

McFarland Clinic - Jefferson
Jefferson 4862482, Iowa 4862182 50129
Contact:
Site Public Contact
515-956-4132

McFarland Clinic - Marshalltown
Marshalltown 4866371, Iowa 4862182 50158
Contact:
Site Public Contact
515-956-4132

University of Kansas Clinical Research Center
Fairway 4271358, Kansas 4273857 66205
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

HaysMed
Hays 4272782, Kansas 4273857 67601
Contact:
Site Public Contact
785-623-5774

University of Kansas Cancer Center
Kansas City 4273837, Kansas 4273857 66160
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Lawrence Memorial Hospital
Lawrence 4274277, Kansas 4273857 66044
Contact:
Site Public Contact
785-505-2800
Stephanie.Norris@LMH.ORG

The University of Kansas Cancer Center - Olathe
Olathe 4276614, Kansas 4273857 66061
Contact:
Site Public Contact
913-355-3943
atheCCResearch@kumc.edu

University of Kansas Cancer Center-Overland Park
Overland Park 4276873, Kansas 4273857 66210
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Hospital-Indian Creek Campus
Overland Park 4276873, Kansas 4273857 66211
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Salina Regional Health Center
Salina 4278890, Kansas 4273857 67401
Contact:
Site Public Contact
785-452-7038
mleepers@srhc.com

University of Kansas Health System Saint Francis Campus
Topeka 4280539, Kansas 4273857 66606
Contact:
Site Public Contact
785-295-8000

University of Kansas Hospital-Westwood Cancer Center
Westwood 4281639, Kansas 4273857 66205
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kentucky/Markey Cancer Center
Lexington 4297983, Kentucky 6254925 40536
Contact:
Site Public Contact
859-257-3379

Lafayette Family Cancer Center-EMMC
Brewer 4959233, Maine 4971068 04412
Contact:
Site Public Contact
800-987-3005

Kaiser Permanente-Woodlawn Medical Center
Baltimore 4347778, Maryland 4361885 21244
Contact:
Site Public Contact
301-816-7218

Kaiser Permanente-Gaithersburg Medical Center
Gaithersburg 4355843, Maryland 4361885 20879
Contact:
Site Public Contact
301-816-7218

Kaiser Permanente - Largo Medical Center
Largo 4360345, Maryland 4361885 20774
Contact:
Site Public Contact
301-816-7446

Kaiser Permanente Lutherville - Timonium Medical Center
Lutherville 4361379, Maryland 4361885 21093
Contact:
Site Public Contact
410-847-3000

UMass Memorial Medical Center - University Campus
Worcester 4956184, Massachusetts 6254926 01655
Contact:
Site Public Contact
508-856-3216
cancer.research@umassmed.edu

Trinity Health Saint Joseph Mercy Hospital Ann Arbor
Ann Arbor 4984247, Michigan 5001836 48106
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Brighton
Brighton 4986994, Michigan 5001836 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Medical Center - Brighton
Brighton 4986994, Michigan 5001836 48114
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Canton
Canton 4987990, Michigan 5001836 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health Medical Center - Canton
Canton 4987990, Michigan 5001836 48188
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Chelsea Hospital
Chelsea 4988628, Michigan 5001836 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
Chelsea 4988628, Michigan 5001836 48118
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Cancer Hematology Centers - Flint
Flint 4992982, Michigan 5001836 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Genesee Hematology Oncology PC
Flint 4992982, Michigan 5001836 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Genesys Hurley Cancer Institute
Flint 4992982, Michigan 5001836 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

Hurley Medical Center
Flint 4992982, Michigan 5001836 48503
Contact:
Site Public Contact
810-762-8038
wstrong@ghci.org

University of Michigan Health - Sparrow Lansing
Lansing 4998830, Michigan 5001836 48912
Contact:
Site Public Contact
517-364-3712
harsha.trivedi@umhsparrow.org

Trinity Health Saint Mary Mercy Livonia Hospital
Livonia 4999837, Michigan 5001836 48154
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

MyMichigan Medical Center Saginaw
Saginaw 5007989, Michigan 5001836 48601
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Oncology Hematology Associates of Saginaw Valley PC
Saginaw 5007989, Michigan 5001836 48604
Contact:
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

MyMichigan Medical Center Tawas
Tawas City 5011900, Michigan 5001836 48764
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Saint Mary's Oncology/Hematology Associates of West Branch
West Branch 5014413, Michigan 5001836 48661
Contact:
Site Public Contact
989-907-8411
lori.srebinski@ascension.org

Huron Gastroenterology PC
Ypsilanti 5015688, Michigan 5001836 48106
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
Ypsilanti 5015688, Michigan 5001836 48197
Contact:
Site Public Contact
734-712-7251
MCRCwebsitecontactform@stjoeshealth.org

Sanford Joe Lueken Cancer Center
Bemidji 5017822, Minnesota 5037779 56601
Contact:
Site Public Contact
218-333-5000
OncologyClinicalTrialsFargo@sanfordhealth.org

Essentia Health - Deer River Clinic
Deer River 5024099, Minnesota 5037779 56636
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Cancer Center
Duluth 5024719, Minnesota 5037779 55805
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Hibbing Clinic
Hibbing 5030005, Minnesota 5037779 55746
Contact:
Site Public Contact
218-786-3308

Essentia Health Sandstone
Sandstone 5045908, Minnesota 5037779 55072
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Essentia Health Virginia Clinic
Virginia 5051468, Minnesota 5037779 55792
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Baptist Memorial Hospital and Cancer Center-Golden Triangle
Columbus 4422442, Mississippi 4436296 39705
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Cancer Center-Grenada
Grenada 4428539, Mississippi 4436296 38901
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Union County
New Albany 4438121, Mississippi 4436296 38652
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Oxford
Oxford 4440076, Mississippi 4436296 38655
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Desoto
Southhaven 4446702, Mississippi 4436296 38671
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Saint Francis Medical Center
Cape Girardeau 4379966, Missouri 4398678 63703
Contact:
Site Public Contact
573-334-2230
sfmc@sfmc.net

Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters 4407237, Missouri 4398678 63376
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center at West County Hospital
Creve Coeur 4382837, Missouri 4398678 63141
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

University Health Truman Medical Center
Kansas City 4393217, Missouri 4398678 64108
Contact:
Site Public Contact
816-404-4375

University of Kansas Cancer Center - North
Kansas City 4393217, Missouri 4398678 64154
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Cancer Center - Lee's Summit
Lee's Summit 4394870, Missouri 4398678 64064
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City 4400860, Missouri 4398678 64116
Contact:
Site Public Contact
913-588-3671
KUCC_Navigation@kumc.edu

Washington University School of Medicine
St Louis 4407066, Missouri 4398678 63110
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center-South County
St Louis 4407066, Missouri 4398678 63129
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Siteman Cancer Center at Christian Hospital
St Louis 4407066, Missouri 4398678 63136
Contact:
Site Public Contact
800-600-3606
info@siteman.wustl.edu

Community Hospital of Anaconda
Anaconda 5637146, Montana 5667009 59711
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Billings Clinic Cancer Center
Billings 5640350, Montana 5667009 59101
Contact:
Site Public Contact
800-996-2663
research@billingsclinic.org

Bozeman Health Deaconess Hospital
Bozeman 5641727, Montana 5667009 59715
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Benefis Sletten Cancer Institute
Great Falls 5655240, Montana 5667009 59405
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Logan Health Medical Center
Kalispell 5660340, Montana 5667009 59901
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Community Medical Center
Missoula 5666639, Montana 5667009 59804
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

OptumCare Cancer Care at Seven Hills
Henderson 5505411, Nevada 5509151 89052
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Charleston
Las Vegas 5506956, Nevada 5509151 89102
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

OptumCare Cancer Care at Fort Apache
Las Vegas 5506956, Nevada 5509151 89148
Contact:
Site Public Contact
702-384-0013
research@sncrf.org

New Hampshire Oncology Hematology PA-Concord
Concord 5084868, New Hampshire 5090174 03301
Contact:
Site Public Contact
603-224-2556

Solinsky Center for Cancer Care
Manchester 5089178, New Hampshire 5090174 03103
Contact:
Site Public Contact
800-339-6484

Memorial Sloan Kettering Basking Ridge
Basking Ridge 5095409, New Jersey 5101760 07920
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Monmouth
Middletown 5101170, New Jersey 5101760 07748
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Bergen
Montvale 5101361, New Jersey 5101760 07645
Contact:
Site Public Contact
212-639-7592

Virtua Samson Cancer Center
Moorestown 4503106, New Jersey 5101760 08057
Contact:
Site Public Contact
856-206-4721
nctn@pennmedicine.upenn.edu

Virtua Voorhees
Voorhees Township 5105860, New Jersey 5101760 08043
Contact:
Site Public Contact
856-247-7395
nctn@pennmedicine.upenn.edu

Memorial Sloan Kettering Commack
Commack 5113412, New York 5128638 11725
Contact:
Site Public Contact
212-639-7592

Mary Imogene Bassett Hospital
Cooperstown 5113664, New York 5128638 13326
Contact:
Site Public Contact
877-547-1750
CancerClinicalTrials@bassett.org

Memorial Sloan Kettering Westchester
Harrison 5120095, New York 5128638 10604
Contact:
Site Public Contact
212-639-7592

Memorial Sloan Kettering Cancer Center
New York 5128581, New York 5128638 10065
Contact:
Site Public Contact
212-639-7592

University of Rochester
Rochester 5134086, New York 5128638 14642
Contact:
Site Public Contact
585-275-5830

Memorial Sloan Kettering Nassau
Uniondale 5141927, New York 5128638 11553
Contact:
Site Public Contact
212-639-7592

Sanford Bismarck Medical Center
Bismarck 5688025, North Dakota 5690763 58501
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Broadway Medical Center
Fargo 5059163, North Dakota 5690763 58122
Contact:
Site Public Contact
701-323-5760
OncologyClinicalTrialsFargo@sanfordhealth.org

Sanford Roger Maris Cancer Center
Fargo 5059163, North Dakota 5690763 58122
Contact:
Site Public Contact
701-234-6161
OncologyClinicalTrialsFargo@sanfordhealth.org

Aultman Health Foundation
Canton 5149222, Ohio 5165418 44710
Contact:
Site Public Contact
330-363-7274
ClinicalReserachDept@aultman.com

Miami Valley Hospital South
Centerville 4508204, Ohio 5165418 45459
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Hospital
Dayton 4509884, Ohio 5165418 45409
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Premier Blood and Cancer Center
Dayton 4509884, Ohio 5165418 45409
Contact:
Site Public Contact
937-276-8320

Miami Valley Hospital North
Dayton 4509884, Ohio 5165418 45415
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Atrium Medical Center-Middletown Regional Hospital
Franklin 4512203, Ohio 5165418 45005-1066
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Miami Valley Cancer Care and Infusion
Greenville 5156493, Ohio 5165418 45331
Contact:
Site Public Contact
937-569-7515

ProMedica Flower Hospital
Sylvania 5173572, Ohio 5165418 43560
Contact:
Site Public Contact
419-824-1842
PCIOncResearch@promedica.org

Upper Valley Medical Center
Troy 5174358, Ohio 5165418 45373
Contact:
Site Public Contact
937-528-2900
clinical.trials@daytonncorp.org

Cancer Centers of Southwest Oklahoma Research
Lawton 4540737, Oklahoma 4544379 73505
Contact:
Site Public Contact
877-231-4440

University of Oklahoma Health Sciences Center
Oklahoma City 4544349, Oklahoma 4544379 73104
Contact:
Site Public Contact
405-271-8777
ou-clinical-trials@ouhsc.edu

Providence Newberg Medical Center
Newberg 5742726, Oregon 5744337 97132
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Saint Alphonsus Cancer Care Center-Ontario
Ontario 5744166, Oregon 5744337 97914
Contact:
Site Public Contact
406-969-6060
mccinfo@mtcancer.org

Providence Willamette Falls Medical Center
Oregon City 5744253, Oregon 5744337 97045
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Portland Medical Center
Portland 5746545, Oregon 5744337 97213
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Providence Saint Vincent Medical Center
Portland 5746545, Oregon 5744337 97225
Contact:
Site Public Contact
503-215-2614
CanRsrchStudies@providence.org

Oregon Health and Science University
Portland 5746545, Oregon 5744337 97239
Contact:
Site Public Contact
503-494-1080
trials@ohsu.edu

WellSpan Medical Oncology and Hematology
Chambersburg 4557109, Pennsylvania 6254927 17201
Contact:
Site Public Contact
717-217-6020

Geisinger Medical Center
Danville 5186327, Pennsylvania 6254927 17822
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Ephrata Cancer Center
Ephrata 5188815, Pennsylvania 6254927 17522
Contact:
Site Public Contact
717-721-4840

Adams Cancer Center
Gettysburg 4558183, Pennsylvania 6254927 17325
Contact:
Site Public Contact
877-441-7957

Sechler Family Cancer Center
Lebanon 5197517, Pennsylvania 6254927 17042
Contact:
Site Public Contact
717-741-8303
doxenberg@wellspan.org

Geisinger Medical Oncology-Lewisburg
Lewisburg 5197842, Pennsylvania 6254927 17837
Contact:
Site Public Contact
570-374-8555
HemonCCTrials@geisinger.edu

Community Medical Center
Scranton 5211303, Pennsylvania 6254927 18510
Contact:
Site Public Contact
570-703-4768
HemonCCTrials@geisinger.edu

Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre 5219488, Pennsylvania 6254927 18711
Contact:
Site Public Contact
570-271-5251
HemonCCTrials@geisinger.edu

Cancer Care Associates of York
York 4562407, Pennsylvania 6254927 17403
Contact:
Site Public Contact
717-741-9229

WellSpan Health-York Cancer Center
York 4562407, Pennsylvania 6254927 17403
Contact:
Site Public Contact
877-441-7957

WellSpan Health-York Hospital
York 4562407, Pennsylvania 6254927 17403
Contact:
Site Public Contact
877-441-7957

Medical University of South Carolina
Charleston 4574324, South Carolina 4597040 29425
Contact:
Site Public Contact
843-792-9321
hcc-clinical-trials@musc.edu

Sanford Cancer Center Oncology Clinic
Sioux Falls 5231851, South Dakota 5769223 57104
Contact:
Site Public Contact
605-312-3320
OncologyClinicTrialsSF@sanfordhealth.org

Sanford USD Medical Center - Sioux Falls
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Contact:
Site Public Contact
605-312-3320
OncologyClinicalTrialsSF@SanfordHealth.org

Baptist Memorial Hospital and Cancer Center-Collierville
Collierville 4614748, Tennessee 4662168 38017
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

Baptist Memorial Hospital and Cancer Center-Memphis
Memphis 4641239, Tennessee 4662168 38120
Contact:
Site Public Contact
901-226-1366
BCCclintrials@bmhcc.org

The Don and Sybil Harrington Cancer Center
Amarillo 5516233, Texas 4736286 79106
Contact:
Site Public Contact
806-212-1985
Gina.Cravey@bsahs.org

Kaiser Permanente Tysons Corner Medical Center
McLean 4772354, Virginia 6254928 22102
Contact:
Site Public Contact
240-632-4284

Kaiser Permanente-Caton Hill Medical Center
Woodbridge 4794457, Virginia 6254928 22192
Contact:
Site Public Contact
Leslie.K.Greenberg@kp.org

Swedish Cancer Institute-Edmonds
Edmonds 5793427, Washington 5815135 98026
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Swedish Cancer Institute-Issaquah
Issaquah 5798487, Washington 5815135 98029
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Swedish Medical Center-First Hill
Seattle 5809844, Washington 5815135 98122
Contact:
Site Public Contact
206-215-3086
PCRC-NCORP@Swedish.org

Edwards Comprehensive Cancer Center
Huntington 4809537, West Virginia 4826850 25701
Contact:
Site Public Contact
304-399-6566
Christina.Cole@chhi.org

Duluth Clinic Ashland
Ashland 5244247, Wisconsin 5279468 54806
Contact:
Site Public Contact
218-786-3308
CancerTrials@EssentiaHealth.org

Marshfield Medical Center-EC Cancer Center
Eau Claire 5251436, Wisconsin 5279468 54701
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Gundersen Lutheran Medical Center
La Crosse 5258957, Wisconsin 5279468 54601
Contact:
Site Public Contact
608-775-2385
cancerctr@gundersenhealth.org

Marshfield Medical Center-Marshfield
Marshfield 5261969, Wisconsin 5279468 54449
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Marshfield Medical Center - Minocqua
Minocqua 5263156, Wisconsin 5279468 54548
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Marshfield Medical Center-River Region at Stevens Point
Stevens Point 5274644, Wisconsin 5279468 54482
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

Marshfield Medical Center - Weston
Weston 5278693, Wisconsin 5279468 54476
Contact:
Site Public Contact
800-782-8581
oncology.clinical.trials@marshfieldresearch.org

More Details

NCT ID
NCT06031688
Status
Recruiting
Sponsor
SWOG Cancer Research Network

Study Contact

Jennifer Beeler
2106148808
jbeeler@swog.org

Detailed Description

PRIMARY OBJECTIVE: I. To compare the response rate (confirmed or unconfirmed, complete or impartial) between participants with MET exon 14 skipping positive non-small cell lung cancer (NSCLC) randomized to tepotinib with or without ramucirumab. SECONDARY OBJECTIVES: I. To compare the frequency of all-grade treatment- related peripheral edema as defined by Common Terminology Criteria for Adverse Events (CTCAE) between the arms. II. To evaluate the frequency and severity of toxicities within each arm. III. To compare progression-free survival between the arms. IV. To compare overall survival between the arms. V. To estimate the duration of response (DoR) among responders within each arm. TRANSLATIONAL MEDICINE OBJECTIVE: I. To establish a tissue/blood repository for participants with MET exon 14 skipping non-small cell lung cancer (NSCLC). OUTLINE: Patients are randomized to 1 of 2 arms. ARM A: Patients receive ramucirumab intravenously (IV) over 30-60 minutes on day 1 of each cycle and tepotinib orally (PO) once daily (QD) on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM B: Patients receive tepotinib PO QD on days 1-21 of each cycle. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo lymphoscintigraphy scan and computed tomography (CT) scan and/or magnetic resonance imaging (MRI) throughout the trial. Patients also undergo blood sample collection while on study. After completion of study treatment, patients are followed-up every 12 weeks or more often as clinically indicated until progression and then every 6 months for 2 years and at the end of 3 years from date of sub-study randomization.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.